Considerations of using oral nucleos(t)ide analogues to interrupt mother-to-child transmission in HBV carrier pregnant woman with high viral load
10.3760/cma.j.issn.1007-3418.2019.02.002
- VernacularTitle: 高病毒载量乙型肝炎病毒携带孕妇是否需要口服核苷（酸）类似物阻断母婴传播？
- Author:
Yang DING
1
;
Qiuju SHENG
;
Xiaoguang DOU
Author Information
1. Department. of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang 110022, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Mother-to-child transmission;
Nucleos(t)ide analogues;
Therapy
- From:
Chinese Journal of Hepatology
2019;27(2):85-87
- CountryChina
- Language:Chinese
-
Abstract:
The main transmission route of chronic hepatitis B virus infection is mother-to-child transmission of hepatitis B virus and the main cause of combined immune prophylaxis failure in neonates at the end of pregnancy is high viral load. Moreover, oral administration of nucleos(t)ide analogues (NAs) during the second and third trimesters of pregnancy can significantly reduce or even completely block mother-to-child transmission of HBV. This article focuses on the necessity and feasibility of oral NAs antiviral therapy for HBV carrier pregnant woman with high viral load, and the issues commences at the time of medication and viral load thresholds.
